FDA MedWatch Drug Alerts
August 7th, 2009
The US FDA has advised healthcare practitioners and consumers of current safety information with regard to body building and increase muscle mass products, these products are commonly described as a substitute for anabolic steroids (used to increase muscle mass and strength), available both online and in retail establishments.
August 7th, 2009
The FDA’s laboratory analysis discovered sulfoaildenafil, an analog of sildenafil. Sildenafil is a key ingredient in the FDA-approved drug for erectile dysfunction, which makes Steam an unsanctioned drug.
August 7th, 2009
The US FDA requires TNF blockers to include firm detailed warnings in the prescribing information. The warnings, which also involves an up to date box warning, spotlights the increase chance of cancer in children and adolescents who first obtain the drug to treat juvenile rheumatoid arthritis, inflammatory bowel disease, Crohn's disease and other inflammatory diseases.
August 7th, 2009
The US FDA cautions consumers of the harmful effects Clarcon skin products are having on the skin. They urge consumers to cease all usage of Clarcon Biological Chemistry Laboratory skin sanitizer or protectants, because of hazardous bacteria.
August 7th, 2009
The US FDA has announced and advised healthcare providers of modifications to the well-known drug names for Botox / Botox Cosmetics, Dysport and Myobloc. These modifications are in the hopes to provide healthcare professionals advice on how to avoid medication inaccuracy, and reinforce individual potency. The modifications are also to provide additional information to patients, family members and caregivers.
August 7th, 2009
Recently, Ranbaxy Pharmaceuticals Inc. announced their voluntary recall of all Nitrofurantoin Capsules lot (USP 100 mg capsules), that currently exist on the U.S. marke
August 7th, 2009
The US FDA is dedicated to fraudulent enforcement with regards to illegal online product marketing claiming to prevent, diagnose, treat and cure the 2009 H1N1 flu virus.
August 6th, 2009
The US FDA recently announced that it will demand that some immunosuppressant drug manufacturers used in kidney (renal) transplants update their labels to disclose a increased risk of infection
August 6th, 2009
The US FDA is to conduct a safety review of asthma treatment drug Xolair. Xolair is a drug primarily used to treat adults and adolescents who suffer from moderate-to-severe persistent asthma.
